# Staccato Loxapine Multidose PK

> **NCT00555412** · PHASE1 · COMPLETED · sponsor: **Alexza Pharmaceuticals, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Volunteers on Chronic, Stable Antipsychotic Regimens

## Interventions

- **DRUG:** A - 10 mg loxapine q 4 h x 3 (30 mg total)
- **DRUG:** B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)
- **DRUG:** C - 5 mg loxapine q 4 h x 3 (15 mg total)
- **DRUG:** D - inhaled placebo q 4 h x 3

## Key facts

- **NCT ID:** NCT00555412
- **Lead sponsor:** Alexza Pharmaceuticals, Inc.
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00555412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00555412, "Staccato Loxapine Multidose PK". Retrieved via AI Analytics 2026-08-25 from https://api.ai-analytics.org/clinical/NCT00555412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*